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Abstract
The biomedical world relies heavily on the definition of pharmaceutical targets as an essential step
in the drug design process. It is therefore tempting to apply this model to genetic diseases as well.
However, whereas the model applies well to gain-of-function genetic diseases, it is less suited to
most loss-of-function genetic diseases. Most common diseases, as well as gain-of-function genetic
diseases, are characterized by the activation of specific pathways or the ectopic activity of proteins,
which make well identified targets. By contrast, loss-of-function genetic diseases are caused by the
impairment of one protein, with potentially distributed consequences. For such diseases, the
definition of a pharmaceutical target is less precise, and the identification of pharmaceutically-
relevant targets may be difficult. This critical but largely ignored aspect of loss-of-function genetic
diseases should be taken into consideration to avoid the commitment of resources to
inappropriate strategies in the search for treatments.
Target identification in the drug discovery 
process
Target identification is an essential first step in today's
drug discovery process. This principle is built on the
premises that, to be efficient, drug development must be
directed against identified biological mechanisms at
molecular level (pharmaceutical targets). This concept is
the core of modern drug discovery and is the primary dif-
ference between modern and former drug discovery,
when drugs were discovered more empirically than
rationally, and were put on the market without much
knowledge of their targets. Today's drug discovery has, by
contrast, become largely target-dependent [1]. The indus-
try standard for drug discovery is defined by an almost
invariant frame consisting of sequential steps: target iden-
tification, target validation, compound screening/design,
compound optimization, preclinical (animal) trials, and
clinical trials (Figure 1) [2,3].
This conception of the drug discovery process is com-
monly accepted beyond the industrial world and is deeply
rooted into the biomedical field, including academia. The
sequencing of large genomes is often justified as a way to
enlarge the repertoire of targets [2]. The sequencing of the
human genome, for instance, was sold as such to the deci-
sion-makers. The pharmaceutical industry's appetite for
targets is filled by academic laboratories and by spin-off
companies specialized in the commercial identification of
targets. Although the pharmaceutical industry has experi-
enced a decline in bringing new drugs to the market in
recent years, the target-based approach remains by far the
dominating drug discovery paradigm [3,4].
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Since rare diseases were neglected for decades by both pol-
icy-makers and industry, drug discovery for rare diseases
has a relatively short history, and remains a dwarf in terms
of expenditure when compared to drug discovery for com-
mon diseases (cardiovascular diseases, cancer, diabetes,
Alzheimer's disease, etc.). It may, therefore, sound like a
reasonable endeavor to apply to an emerging field a strat-
egy that is the standard in another not-so-distant field. For
this reason, when it comes to genetic diseases, a shared
view exists within the scientific community that the target-
based drug development concept should apply to genetic
diseases as it does to non-heritable diseases. This one-size-
fits-all strategy is conservative but, as we will see, may not
be the optimal strategy, since some genetic diseases are
only poorly adapted to it.
Genetic diseases fitting the concept of a 
therapeutic target
Gain-of-function diseases
Gain-of-function (gof) genetic diseases, as the term indi-
cates, are caused by the ectopic or increased activity of the
mutated gene product. Proteins mutated in gof diseases
may or may not carry a dominant-negative effect. Ectopic
or increased protein activity most often turns on cellular
processes that normally do not occur in a healthy cell,
thereby triggering a pathology. In this respect, gain-of-
function genetic diseases are comparable to the common
diseases that are in the focus of the pharmaceutical indus-
try (cancer, stroke, infectious diseases, Alzheimer's dis-
ease) and that may also be defined, in first approximation,
as an activation of pathological cellular processes that do
not occur in a healthy cell. Therefore, it is of no surprise
that the concept of the target-based drug design applies
well to this class of diseases. Who could claim to have a
better approach against polyglutamine expansion dis-
eases, for instance, than neutralizing the faulty protein
and blocking the downstream chain of deleterious events?
Loss-of-function diseases
A small proportion of loss-of-function (lof) genetic dis-
eases are also well-suited to the concept of target-based
drug design. These are mostly diseases with a simple and
well-understood physiopathology, like channelopathies
and some metabolic diseases. In such diseases, the reduc-
tion of a cellular function resulting from the mutation
may be pharmacologically corrected by either stimulating
this function or inhibiting an opposite function (Figure
2). For instance, in Myotonia congenita (a recessive dis-
ease caused by mutations in the chloride channel gene
CLCN1), malfunction of the chloride channel impairs the
skeletal muscle repolarization, the voltage-dependent
sodium channels are improperly opened, and a subse-
quent myotonia ensues. Myotonia symptoms can be effec-
tively reduced by a sodium channel antagonist,
mexiletine, which decreases the muscle excitability, and
thereby re-establishes the balance between excitation and
relaxation [5] (Figure 2A). The concept of pharmaceutical
targets (chloride channel and sodium channel in this
case) makes perfect sense here because i) the physiology
of muscle excitation is well-known and ii) channels are
highly amenable to modulation by drugs.
Another example is provided by metabolic diseases. Met-
abolic diseases are a physiologically-damaging alteration
in the amount of a key cellular metabolite, and are often
caused by loss-of-function mutations in enzyme-encod-
ing genes. When supplementation treatments are not pos-
sible, metabolic diseases may be treated by
pharmacological strategies aimed at restoring an appro-
priate level of the key metabolite by playing with adjacent
metabolic pathways (Figure 2B). Here again, the relatively
The canonical steps of modern drug discovery Figure 1
The canonical steps of modern drug discovery. Target 
identification is the first and obligatory step in the canonical 
paradigm of drug discovery.Orphanet Journal of Rare Diseases 2007, 2:30 http://www.OJRD.com/content/2/1/30
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simple physiopathology allows for an easy identification
of therapeutic targets.
Genetic diseases for which the concept of a 
pharmaceutical target is, at best, vague
Unfortunately, the concept of a pharmaceutical target fits
poorly with the majority of loss-of-function genetic dis-
eases. This is due to the specific position that loss-of-func-
tion genetic diseases occupy in the spectrum of disorders:
it is conceptually difficult to correct the absence of a pro-
tein by pharmacological means (Figure 3). This simple
but largely overlooked fact has broad implications for
drug discovery.
Duchenne muscular dystrophy (DMD), one of the most
studied genetic diseases, is due to the impairment of dys-
trophin, a structural protein underlying the muscle mem-
brane. After 20 years of research on dystrophin, neither
the role of dystrophin in a healthy muscle nor the physio-
pathology of the disease are fully understood yet [6,7]. It
is established that the absence of a functional dystrophin
results in muscle fibre calcium overload, mislocalization
of signaling proteins, and membrane fragility. Calcium
overload may in turn translate into dozens of secondary
effects, ranging from increased muscle excitability to
improper caspase activation. Mislocalization of signaling
proteins and membrane fragility, the two other main traits
of DMD, may also be subdivided into numerous items,
some of them being deleterious and others not. What,
then, causes the end-point phenotype of progressive mus-
cle necrosis? Is it just one of the many secondary effectors
or, more likely, a combination of several of them? As in
many other diseases affecting structural proteins, the loss-
of-function mutation has a pleiotropic effect, distributed
amongst various cellular functions, pathways and com-
partments.
Pleiotropy is also a hallmark of diseases affecting genes
involved in central cellular processes: DNA replication
and maintenance, transcription and RNA processing, pro-
tein maturation, trafficking, etc. Spinal muscular atrophy
type I (SMA 1), one of the most frequent genetic diseases,
is caused by mutations in the SMN gene. Although the
genetics of the SMN locus is complex, it can be considered
as a lof disease, since it results in a reduction of functional
SMN protein. The SMN protein plays a role in spliceo-
somal snRNP biogenesis, and SMN mutations seem to
result in a shortage of functional spliceosomes [8,9],
thereby globally perturbing mRNA processing. The
number of misprocessed mRNA species is not yet fully
Only a few specific loss-of-function genetic diseases match the concept of a pharmaceutical target Figure 2
Only a few specific loss-of-function genetic diseases match the concept of a pharmaceutical target. Although the 
concept of a pharmaceutical target does not fit most loss-of-function diseases, channelopathies and some metabolic diseases 
are exceptions to the rule. A) Schematic view of putative strategies to treat a partial loss-of-function affecting an ion channel. 
Agonists may stimulate the channel to increase its activity. Alternatively, antagonists of opposite-effect channels may restore 
the ion balance of the cell. B) Schematic view of putative strategies to treat a loss-of-function disease affecting an enzyme. In 
this example, the reduction of enzyme activity (blue cross) results in a deficit in a key metabolite A. This deficit may be com-
pensated by inhibiting A-transforming enzymes (1), increasing the abundance of a precursor (2), and stimulating A-producing 
enzymes (3). (Supplementation of A, also a therapeutic possibility for some disorders, is not shown.)Orphanet Journal of Rare Diseases 2007, 2:30 http://www.OJRD.com/content/2/1/30
Page 4 of 6
(page number not for citation purposes)
established, but is probably very large. How many of them
contribute to the progressive death of motorneurons?
Probably more than just a few.
As with the mRNA processing genes, so too with the tran-
scription factor genes. How many misregulated genes are
responsible for the numerous symptoms observed in Clei-
docranial dysplasia (CCD) and Waardenburg syndrome,
to mention only these two diseases among the many
affecting transcription factors?
What are the pharmaceutical targets for Emery-Dreifuss
dystrophy (mutation in a nuclear envelope protein), for
Schwartz-Jampel disease (mutation in the basement
membrane protein perlecan), for Centronuclear congeni-
tal myopathy (mutation in dynamin, a transport vesicle
protein)?
These few examples demonstrate that the concept of a
pharmaceutical target – a biochemical entity which can be
levered by a drug – is unsuitable to many loss-of-function
genetic diseases.
Risks and difficulties of applying the «target-
first» strategy to physiologically complex 
genetic diseases
Twenty years ago, in the early days of human molecular
genetics, the scientific community propagated the errone-
ous idea that, once a disease gene was identified, the treat-
ment would be around the corner. The following years
Schematic view of the physiological consequences and possible countermeasures against gain-of-function and loss-of-function  mutations Figure 3
Schematic view of the physiological consequences and possible countermeasures against gain-of-function and 
loss-of-function mutations. In this example, the protein of interest (pink octogon) normally supports the assembly of a pro-
tein complex. (LEFT) In the wild-type situation, a complex is formed with other protein partners (blue polygons). (MIDDLE) A 
gain-of-function mutation results in the abnormal formation of protein polymers and protein aggregates, which may have con-
stitutive activity or be toxic to the cell. Therapeutic options will consist in neutralizing the mutated protein and blocking the 
formation of aggregates with other proteins; pharmaceutical targets are already identified or may be identified readily in down-
stream pathways. (RIGHT) A loss-of-function mutation will result in the absence of the complex. The biological processes 
depending on the complex will be perturbed. Pharmaceutical targets are more evasive in the loss-of-function situation.Orphanet Journal of Rare Diseases 2007, 2:30 http://www.OJRD.com/content/2/1/30
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have been sobering and disillusioning. We should be care-
ful not to repeat that mistake by spreading another idea,
which might be as over-optimistic as the previous one:
that genetic diseases will be modeled around «targets»,
and that targets will be the key to treatments. In this view,
targets identified by biologists will be passed on to medic-
inal chemists who will design target-based treatments.
This scheme is in line with the contemporary approach of
drug discovery. Unfortunately, when it comes to genetic
diseases, two factors greatly reduce the feasibility of this
strategy: i) the definition of pharmaceutical targets is, at
best, vague, for the majority of lof genetic diseases; ii) to
have some chance of success, a target-designed treatment
against the above-mentioned diseases should be directed
against not one but several targets simultaneously – an
almost impossible challenge.
There is another contextual element which is rarely men-
tionned, but which should also be looked at with open
eyes. The contemporary drug discovery strategy has scored
some spectacular successes on certain fronts. However,
other less successful stories remind us that it is by no
means a trivial matter to battle diseases, even when the
targets are clearly identified and the picture looks simple.
In the fight against infectious diseases, for instance, in
which the pathological process starts by a sequential and
almost linear chain of well-characterized events, we are
still a long way from total victory. The same is true for can-
cer. Some forms of cancer are far from contained, despite
well-known targets and big spending. What then, are the
chances of finding treatments against genetic diseases on
a large scale, by applying the same and, in this case, a less
appropriate strategy with much less money?
What should be done?
1. Invest in the understanding of the physiopathology, but 
not for the reason usually put forward
This dark picture does not mean that money invested in
trying to dissect out the mechanisms underlying physio-
logically complex lof genetic diseases is useless. It is
important to carry on investing in the understanding of
the physiopathology of these diseases, but the main rea-
son to do it might not be the one usually put forward
(finding targets that pharmacologists and chemists will
turn into treatments). Otherwise, the scientific commu-
nity may once again promise more that it can deliver.
The first reason for investing in the understanding of
genetic disease physiopathology is that even though the
efficiency of the «target first» strategy as a global approach
has been overestimated, its fallout on specific diseases
must not be neglected. There will be instances when find-
ings involving the physiopathology will shed light on
mechanisms rapidly amenable to drug therapies, such as
idebenone against Friedreich ataxia [10]. However, such
situations are rare and there is no reason to think that
their proportion will increase.
The main drive to invest in the understanding and the fine
characterization of genetic disease physiopathology is that
it creates a knowledge environment. This knowledge envi-
ronment has at least two benefits: Firstly, it will be an
essential tool to evaluate the efficiency and the mode of
action of future treatments, which may or may not (see
below) originate from a target-based approach. Increasing
the number of available parameters and endpoints allows
for a better appraisal of treatment efficiency. Secondly,
with 5,000 or more genetic diseases around, one hasto
think global. The knowledge environment developed on
each disease (or group of diseases) can be used to chain
Thinking global in the fight against genetic diseases Figure 4
Thinking global in the fight against genetic diseases. 
Genetic diseases (circles) can be put on virtual maps based 
on multiple levels of biological information. Once treatments 
are available for a few diseases, taking advantage of the con-
nections will facilitate the identification of treatments for 
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diseases togetherin a network of information. Genetic dis-
eases, even those for which little is known, can be placed
on interactome-like virtual maps (Figure 4) based on all
sorts of information, ranging from literature keywords to
transcriptome gene clustering and bioprofiling of body
fluids. As treatments appear for some diseases, taking
advantage of the network connections will rapidly pro-
vide therapeutic hints for other still-orphan diseases, and
may constitute the largest payoff of the investment made
on trying to dissect the physiopathology.
2. Consider alternative strategies
It is probably time to reevaluate the choice of the «target
first» strategy as the main option in the search of pharma-
ceutical treatments against physiologically complex lof
genetic diseases. For these diseases, success may well come
from a less ambitious but more pragmatic strategy: the
«screen first, understand later» strategy. This alternative
strategy, also referred to as physiology-based, is of interest
in all indications where no obvious target is available [7].
In the search for treatments against rare diseases, the
bonanza of existing drugs has been surprisingly underex-
ploited up to now. Yet, anecdotal evidence demonstrates
that old drugs can have an unpredicted beneficial effect on
some genetic diseases: colchicine was serendipitously
found to cure Familial mediterranean fever (FMF), and
acetazolamide is active against Episodic ataxia despite any
rationale underlyings. Since these discoveries are the
result of sheer luck (co-occurrence of diseases in one case
and diagnostic error in the other), one can extrapolate that
the pharmacopea contains many more unraveled gems.
Furthermore, beyond approved drugs, chemical libraries
constitute another vast reservoir of potentially useful mol-
ecules against genetic diseases. These chemical resources
should be taken advantage of more thoroughly. Currently,
the limiting factor for molecule identification is the short-
age of high-throughput screening (HTS) systems. For
most genetic diseases, in vitro models either do not exist or
are not suitable for HTS screening. This bottleneck is less
a technological one than the result of insufficient develop-
ment. Committing financial resources to overcome this
limitation and running high-throughput molecule screens
might at the end of the day be one of the most cost-effi-
cient investments in rare disease research.
Conclusion
After being ignored by governments for decades, rare dis-
eases are now a biomedical research priority in most
developed countries. However, the fundamental differ-
ence that exists between loss-of-function genetic diseases
(the most numerous ones) and most other human disor-
ders has been largely overlooked. As a consequence, con-
fusion exists in the definition of what the optimal drug-
discovery strategy against the majority of loss-of-function
diseases is. In-depth reflection is necessary to resolve this
issue and to avoid the commitment of energy and money
to inappropriate research strategies.
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